STOCK TITAN

Lexaria Bioscience Corp - LEXX STOCK NEWS

Welcome to our dedicated news page for Lexaria Bioscience (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexaria Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexaria Bioscience's position in the market.

Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) receives approval from an ethics review board to commence a new GLP-1 study. The study will investigate the effectiveness of DehydraTECH-enabled semaglutide formulations in comparison to Rybelsus®. The company aims to improve drug delivery and blood glucose control through this study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.08%
Tags
none
-
News
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ:LEXX) receives new patents in epilepsy and anti-viral agents, enhancing drug delivery platforms. The company obtained two patents for treating epilepsy in the USA, showcasing effectiveness in mitigating seizures. Additionally, a patent in Japan for enhanced delivery of antiviral agents was granted. Lexaria now holds 41 patents globally, reinforcing its intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the 14th Annual LD Micro Invitational to discuss the enhanced performance of GLP-1 drugs using DehydraTECH. The event will feature 80 companies presenting in half-hour increments, with Lexaria scheduled to present on April 9th, 2024, at 10:30 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
conferences
Rhea-AI Summary
Lexaria Bioscience Corp. appoints Nelson Cabatuan as Chief Financial Officer to drive long-term growth strategy. Mr. Cabatuan brings over 15 years of corporate finance experience in the life sciences industry, enhancing Lexaria's financial operations and potential use of DehydraTECH platform for therapeutic applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
management
-
Rhea-AI Summary
Lexaria Bioscience Corp. announces the initiation of a human pilot study to test the first-ever dissolvable DehydraTECH-GLP-1 oral dose formulation, aiming to revolutionize GLP-1 drug delivery. The study will compare three dose formulations, including a positive control Rybelsus® semaglutide swallowed tablet, DehydraTECH-semaglutide swallowed capsules, and an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. If successful, this innovative delivery method could eliminate the need for painful injections or stomach-upsetting tablets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
none
-
Rhea-AI Summary
Lexaria Bioscience Corp. announces an 8-week animal study to examine the effects of DehydraTECH-processed GLP-1 and CBD formulations on weight loss and blood glucose control. The study will assess brain absorption delivery enhancement and potential benefits for diabetes treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.67%
Tags
none
Rhea-AI Summary
Lexaria Bioscience Corp. announces positive results from a study on its DehydraTECH-CBD formulation, showing weight loss and blood glucose reduction in rodents. The company is progressing to a large animal study and has also reported promising results in a human study. Lexaria aims to further investigate the potential benefits of its formulations for weight loss and blood glucose control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) receives FDA confirmation for IND application, paving the way for a Phase 1b hypertension clinical trial utilizing DehydraTECH-CBD. The milestone achievement demonstrates the technology's efficacy and safety, positioning Lexaria for potential future pharmaceutical commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.36%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. successfully closes a registered direct offering, raising approximately $3.6 million for research and development studies, patent costs, and general working capital. The offering includes the sale of 1,558,443 shares of common stock and unregistered warrants to purchase additional shares at a purchase price of $2.31 per share and an exercise price of $2.185 per share, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Lexaria Bioscience Corp. announces a registered direct offering and private placement of common stock and warrants, aiming to raise funds for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
Lexaria Bioscience Corp

Nasdaq:LEXX

LEXX Rankings

LEXX Stock Data

27.32M
11.14M
8.58%
9%
3.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Kelowna

About LEXX

learn about working at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group. join linkedin today for free. see who you know at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group, leverage your professional network, and get hired.